
|Articles|June 1, 2002
Pimecrolimus goes pharmacogenetic
Previewing what may become routine in a few years, researchers have used genetic profiling to evaluate efficacy and adverse effects of a drug undergoing clinical trials for the treatment of psoriasis.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Envudeucitinib Achieves 54% PASI 100 Rate at 48 Weeks in Phase 3 Extension
2
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
3
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
4
Biologic Therapies in AD and CSU: Progress and the Push for Precision Medicine
5











